Lilly’s TuneLab AI drug platform lands in Schrödinger LiveDesign as biotech access broadens
NEW YORK, Jan 10, 2026, 08:12 (EST) Schrödinger announced it will integrate Eli Lilly’s TuneLab, an AI-driven drug discovery platform, into its LiveDesign software. This move offers biotech teams direct access to Lilly’s predictive models. “LiveDesign will be a priority platform partner for TuneLab workflows,” said Pat Lorton, Schrödinger’s software chief. (FinancialContent) The deal comes as drugmakers ramp up AI…